Startseite › Prostatakrebs › Oregon › Portland
Klinische Studien zu Prostatakrebs in Portland, OR
33 Studien zu Prostatakrebs suchen Teilnehmer an Standorten in und um Portland (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- Oregon Health & Science University (OHSU), Portland
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12 mi entfernt
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
Teilnehmer gesuchtPhase 4
- Oregon Health & Science University, Portland
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
Teilnehmer gesuchtPhase 1
- Oregon Health And Science University, Portland
Precision-Based Genomics in Prostate Cancer
Teilnehmer gesuchtBeobachtungsstudie
- Oregon Health Sciences University, Portland
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Teilnehmer gesuchtPhase 1
- Providence Portland Medical Center, Portland
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
Teilnehmer gesuchtPhase 2
- VA Portland Health Care System, Portland, OR, Portland
Carboplatin or Olaparib for BRcA Deficient Prostate Cancer
Teilnehmer gesuchtPhase 2
- VA Portland Health Care System, Portland, OR, Portland
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Teilnehmer gesuchtPhase 3
- VA Portland Health Care System ( Site 0038), Portland
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Kaiser Permanente Northwest, Portland
MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Teilnehmer gesucht
- Oregon Health & Science University, Portland
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Teilnehmer gesuchtPhase 2
- Oregon Health & Science University, Portland
Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer
Teilnehmer gesuchtPhase 1/2
- Research Site, Portland
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Teilnehmer gesuchtPhase 3
- Research Site, Portland
A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss
Teilnehmer gesuchtPhase 2
- VA Portland Health Care System, Portland, OR, Portland
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- und 1 weitere
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Oregon Health and Science University, Portland
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Teilnehmer gesuchtPhase 3
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- und 1 weitere
A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Teilnehmer gesuchtPhase 1/2
- Oregon Health & Science University, Portland
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Teilnehmer gesuchtPhase 2
- VA Portland Health Care System, Portland
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Teilnehmer gesuchtBeobachtungsstudie
- Oregon Health & Science University Hospital, Portland
Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- OHSU Knight Cancer Institute, Portland
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
Teilnehmer gesuchtPhase 1
- Research Site, Portland
Internet-Based Lifestyle Intervention to Eradicate Obese Frailty in Prostate Cancer Survivors, iLIVE
Teilnehmer gesucht
- OHSU Knight Cancer Institute, Portland
GET FIT Together: Testing a Socially Enhanced Exercise Program in Older Men With Prostate Cancer
Teilnehmer gesucht
- OHSU Knight Cancer Institute, Portland
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation
Teilnehmer gesuchtPhase 2
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- und 1 weitere
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Oregon Health Sciences University, Portland
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Portland
EMBRACE: Exercising Together
Teilnehmer gesuchtPhase 2Gesunde Freiwillige willkommen
- OHSU Knight Cancer Institute, Portland
Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
Teilnehmer gesuchtPhase 2
- VA Portland Healthcare System, Portland
Prostatakrebs-Studien in anderen Städten
- New York City, NY103 Studien
- Houston, TX76 Studien
- Los Angeles, CA61 Studien
- Boston, MA59 Studien
- St. Louis, MO46 Studien
- Chicago, IL45 Studien
- San Francisco, CA45 Studien
- Philadelphia, PA44 Studien
- Baltimore, MD43 Studien
- Nashville, TN42 Studien
- Seattle, WA42 Studien
- Washington, DC38 Studien
Weitere Studien in Portland
- Nichtkleinzelliges Lungenkarzinom46 Studien
- Krebs (alle Arten)34 Studien
- Brustkrebs33 Studien
- Metastasierender Krebs29 Studien
- Kolorektales Karzinom28 Studien
- Eierstockkrebs27 Studien
- Lungenkrebs26 Studien
- Akute myeloische Leukämie25 Studien
- Endometriumkarzinom24 Studien
- Plattenepithelkarzinom im Kopf-Hals-Bereich19 Studien
- Bauchspeicheldrüsenkrebs19 Studien
- Herzinsuffizienz17 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 05.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.